EP1578792A2 - Neuescentrosom-assoziiertes protein und dessen anwendungen - Google Patents

Neuescentrosom-assoziiertes protein und dessen anwendungen

Info

Publication number
EP1578792A2
EP1578792A2 EP03813937A EP03813937A EP1578792A2 EP 1578792 A2 EP1578792 A2 EP 1578792A2 EP 03813937 A EP03813937 A EP 03813937A EP 03813937 A EP03813937 A EP 03813937A EP 1578792 A2 EP1578792 A2 EP 1578792A2
Authority
EP
European Patent Office
Prior art keywords
protein
seq
polynucleotide
asap
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03813937A
Other languages
English (en)
French (fr)
Inventor
Dominique Giorgi
Sylvie Rouquier
Jean-Michel Saffin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Publication of EP1578792A2 publication Critical patent/EP1578792A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Definitions

  • the protein according to the invention consists of the chain of 13 peptides corresponding to the translation products of 13 of the 14 exons that contains the corresponding gene, the first exon not being translated (see below).
  • - Peptide 7 it comprises 24 amino acids corresponding to positions 351 to 374 (SEQ ID NO: 8); - Peptide 8: it comprises 54 amino acids corresponding to positions 375 to 428 (SEQ ID NO: 9);
  • sequences SEQ ID NO: 47 to 53 corresponding to mutants of the hASAP protein deleted from the N-terminal part containing the BRCT domain (NdeM: residues 304 -647 (SEQ ID NO: 48); Ndel2: residues 411-647 (SEQ ID NO: 49); Ndel3: residues 478-647 (SEQ ID NO: 50)) or of the C-terminal part containing the MAP domain (CdeM: residues 1 to 477 (SEQ ID NO: 51); Cdel2: residues 1 to 418 (SEQ ID NO: 52); Cdel3: residues 1 to 303 (SEQ ID NO: 53); residues 1 to 421 (SEQ ID NO: 47)).
  • said peptide is useful for the production of antibodies specifically recognizing a protein as defined above, preferably recognizing the ASAP protein of sequence SEQ ID NO: 1 or SEQ ID NO: 46 .
  • the subject of the invention is also a kit of reagents for the implementation of the methods described above comprising: a) at least one probe or a pair of primers according to the invention; b) the reagents necessary for carrying out a conventional hybridization reaction between said probe or said primers and the nucleic acid of the biological sample; c) the reagents necessary for carrying out an amplification reaction; d) the reagents necessary for the detection and / or the assay of the hybrid formed between said probe and the nucleic acid of the biological sample or of the amplified nucleic acids formed.
  • Such substances can be biological macromolecules such as for example a nucleic acid, a lipid, a sugar, a protein, a peptide, a hybrid protein-lipid compound, protein-sugar, peptide-iipid or peptide-sugar, a protein or a peptide to which chemical ramifications have been added or chemical molecules.
  • the invention also relates to the polynucleotide, the protein, the antibodies, the vectors or the cells transformed according to the invention, used as medicaments.
  • Hoechst 33286 (4A: 63x objective; 4B, 4C, 4D: I00X objective).
  • YFP-FIS1 F (5'-AATGTCTGATGAAG I I I I IAGCACC-3 ') (SEQ ID NO: 41)
  • the vectors obtained are transfected according to the calcium phosphate technique or more routinely using the jetPE1 process (GDSP10101, Qbiogene) according to the manufacturer's recommendations, in the following cell lines:
  • FIG. 5 illustrates the co-location of the human ASAP protein with alpha-tubulin; similarly the murine ASAP protein co-locates with alpha-tubulin.
  • RNAi interfering RNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP03813937A 2002-12-24 2003-12-24 Neuescentrosom-assoziiertes protein und dessen anwendungen Withdrawn EP1578792A2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0216648A FR2849039B1 (fr) 2002-12-24 2002-12-24 Nouvelle proteine associee aux centrosomes et ses applications
FR0216648 2002-12-24
PCT/FR2003/003895 WO2004058815A2 (fr) 2002-12-24 2003-12-24 Proteine associee aux centrosomes et ses applications

Publications (1)

Publication Number Publication Date
EP1578792A2 true EP1578792A2 (de) 2005-09-28

Family

ID=32406499

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03813937A Withdrawn EP1578792A2 (de) 2002-12-24 2003-12-24 Neuescentrosom-assoziiertes protein und dessen anwendungen

Country Status (7)

Country Link
US (2) US7402394B2 (de)
EP (1) EP1578792A2 (de)
JP (1) JP4660200B2 (de)
AU (1) AU2003303464A1 (de)
CA (1) CA2511436A1 (de)
FR (1) FR2849039B1 (de)
WO (1) WO2004058815A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2789446A1 (en) * 2010-02-12 2011-08-18 Oncomed Pharmaceuticals, Inc. Methods for identifying and isolating cells expressing a polypeptide
CN115896146B (zh) * 2022-08-10 2026-04-07 德州学院 荧光蛋白标记的微管蛋白和微管结合蛋白通用型双价载体的构建

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000073801A2 (en) * 1999-05-28 2000-12-07 Ludwig Institute For Cancer Research Breast, gastric and prostate cancer associated antigens and uses therefor
US6783969B1 (en) * 2001-03-05 2004-08-31 Nuvelo, Inc. Cathepsin V-like polypeptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004058815A2 *

Also Published As

Publication number Publication date
AU2003303464A8 (en) 2004-07-22
JP4660200B2 (ja) 2011-03-30
WO2004058815B1 (fr) 2005-05-06
US20060216710A1 (en) 2006-09-28
CA2511436A1 (fr) 2004-07-15
FR2849039B1 (fr) 2010-10-01
JP2006526387A (ja) 2006-11-24
WO2004058815A2 (fr) 2004-07-15
US7402394B2 (en) 2008-07-22
AU2003303464A1 (en) 2004-07-22
FR2849039A1 (fr) 2004-06-25
US20090275024A1 (en) 2009-11-05
WO2004058815A3 (fr) 2005-03-17

Similar Documents

Publication Publication Date Title
EP0868512B9 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
Lim et al. SPIN90 (SH3 ProteinInteracting with Nck, 90 kDa), an Adaptor Protein That Is Developmentally Regulated during Cardiac Myocyte Differentiation
EP1228091A1 (de) Membrane-proteine ctl (choline transporter like) die in dem transport der choline involviert sind
WO2001072822A2 (fr) Genes impliques dans les maladies inflammatoires de l"intestin et leur utilisation
EP0980427B1 (de) Verwendung von ulip proteinen zur diagnose und therapie von krebs und paraneoplastischen neurologischen syndromen
Ahmady et al. Identification of a novel muscle A-type lamin-interacting protein (MLIP)
Fritzius et al. WD‐repeat‐propeller‐FYVE protein, ProF, binds VAMP2 and protein kinase Cζ
EP1578792A2 (de) Neuescentrosom-assoziiertes protein und dessen anwendungen
EP1259606B1 (de) Zur steuerung der parkinaktivität brauchbare zusammensetzungen
EP1268790A1 (de) Erbin kodierendes gen, und ihre anwendung in diagnose und therapie
WO2003040369A2 (fr) Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments
US20030064372A1 (en) Gene and sequence variation associated with lipid disorder
US8138307B2 (en) Parkin interacting polypeptides and methods of use
US20030054418A1 (en) Gene and sequence variation associated with cancer
EP1257642B1 (de) Partnern des ptb1 domäne aus fe65, herstellung und verwendungen davon
WO2003025176A2 (fr) Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments
WO2001085955A1 (fr) Polypeptide rh116 et ses fragments et polynucleotides codant lesdits polypeptides et applications thérapeutiques
WO2003025177A2 (fr) Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments
WO2003087153A1 (fr) Proteine knox-25 en doigt de zinc de type kruppel de souris et son utilisation
WO2001031003A1 (fr) Clonage, expression et caracterisation d'un gene exprime dans des cellules tumorales et implique dans la regulation de la reponse immune
EP1409675A1 (de) An der apoptoseregulation beteiligtes gen
WO2003087372A2 (fr) Facteur de croissance derive d’hepatome et son utilisation
FR2802944A1 (fr) Sequences nucleotidiques codant pour un polypeptide capable d'interagir avec des proteines des familles p300/cbp et rb

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050701

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20080415

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120703